• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

雄激素受体、表皮生长因子受体及乳腺癌1号基因作为三阴性乳腺癌生物标志物的荟萃分析

Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis.

作者信息

Zhang Li, Fang Cheng, Xu Xianqun, Li Anling, Cai Qing, Long Xinghua

机构信息

Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

Hubei University of Chinese Medicine, Wuhan 430061, China.

出版信息

Biomed Res Int. 2015;2015:357485. doi: 10.1155/2015/357485. Epub 2015 Jan 28.

DOI:10.1155/2015/357485
PMID:25695063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4324735/
Abstract

OBJECTIVE

More and more evidences demonstrate that androgen receptor (AR), epidermal growth factor receptor (EGFR), and breast cancer susceptibility gene 1 (BRCA1) have unique clinical implications for targeted therapy or prognosis in triple-negative breast cancer (TNBC). Therefore, we conducted a meta-analysis to summarize the possible associations.

METHODS

We retrieved published articles about AR, EGFR, and BRCA1 in TNBC from PubMed and EMBASE. The analysis was performed with Rev-Man 5.2 software.

RESULTS

A total of 38 articles were eligible for the meta-analysis. Our study showed that the expression level of EGFR (OR = 6.88, P < 0.00001) and the prevalence of BRCA1 mutation (RR = 5.26, P < 0.00001) were higher in TNBC than non-TNBC. In contrast, the expression level of AR was lower in TNBC than non-TNBC (OR = 0.07, P < 0.00001). In the subgroup related to EGFR expression, the level of EGFR expression was significantly increased in Asians (OR = 9.60) compared with Caucasians (OR = 5.53) for TNBC patients. Additionally, the prevalence of BRCA1 mutation in Asians (RR = 5.43, P < 0.00001) was higher than that in Caucasians (RR = 5.16, P < 0.00001).

CONCLUSIONS

The distinct expression of AR and EGFR and the prevalence of BRCA1 mutation indicated that AR, EGFR, and BRCA1 might be unique biomarkers for targeted therapy and prognosis in TNBC.

摘要

目的

越来越多的证据表明，雄激素受体（AR）、表皮生长因子受体（EGFR）和乳腺癌易感基因1（BRCA1）在三阴性乳腺癌（TNBC）的靶向治疗或预后方面具有独特的临床意义。因此，我们进行了一项荟萃分析以总结可能的关联。

方法

我们从PubMed和EMBASE检索了关于TNBC中AR、EGFR和BRCA1的已发表文章。使用Rev-Man 5.2软件进行分析。

结果

共有38篇文章符合荟萃分析的条件。我们的研究表明，TNBC中EGFR的表达水平（OR = 6.88，P < 0.00001）和BRCA1突变的发生率（RR = 5.26，P < 0.00001）高于非TNBC。相比之下，TNBC中AR的表达水平低于非TNBC（OR = 0.07，P < 0.00001）。在与EGFR表达相关的亚组中，TNBC患者中亚洲人的EGFR表达水平（OR = 9.60）比高加索人（OR = 5.53）显著升高。此外，亚洲人BRCA1突变的发生率（RR = 5.43，P < 0.00001）高于高加索人（RR = 5.16，P < 0.00001）。

结论

AR和EGFR的不同表达以及BRCA1突变的发生率表明，AR、EGFR和BRCA1可能是TNBC靶向治疗和预后的独特生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/1374b185eec6/BMRI2015-357485.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/432c96dc09ac/BMRI2015-357485.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/8ecaa7032508/BMRI2015-357485.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/bd2be89dfc1b/BMRI2015-357485.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/80d95faac89b/BMRI2015-357485.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/e15baba25d15/BMRI2015-357485.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/f9c6cd9ed25c/BMRI2015-357485.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/1374b185eec6/BMRI2015-357485.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/432c96dc09ac/BMRI2015-357485.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/8ecaa7032508/BMRI2015-357485.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/bd2be89dfc1b/BMRI2015-357485.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/80d95faac89b/BMRI2015-357485.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/e15baba25d15/BMRI2015-357485.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/f9c6cd9ed25c/BMRI2015-357485.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df2c/4324735/1374b185eec6/BMRI2015-357485.007.jpg

相似文献

1
Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis.雄激素受体、表皮生长因子受体及乳腺癌1号基因作为三阴性乳腺癌生物标志物的荟萃分析
Biomed Res Int. 2015;2015:357485. doi: 10.1155/2015/357485. Epub 2015 Jan 28.
2
Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.Claudin 3和表皮生长因子受体表达差异可预测三阴性乳腺癌中的BRCA1突变
Cancer Invest. 2018;36(7):378-388. doi: 10.1080/07357907.2018.1499934. Epub 2018 Aug 24.
3
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.雄激素受体阳性三阴性乳腺癌中PARP1与BRCA1的相关性
Int J Biol Sci. 2016 Nov 25;12(12):1500-1510. doi: 10.7150/ijbs.16176. eCollection 2016.
4
High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.巴基斯坦三阴性乳腺癌患者中BRCA1种系突变的高患病率和优势地位。
BMC Cancer. 2016 Aug 23;16(1):673. doi: 10.1186/s12885-016-2698-y.
5
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.雄激素受体和 FOXA1 共表达在非转移性三阴性乳腺癌中的预后价值及与其他生物标志物的相关性。
Br J Cancer. 2018 Jul;119(1):76-79. doi: 10.1038/s41416-018-0142-6. Epub 2018 Jun 8.
6
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.BRCA1-IRIS失活克服三阴性乳腺癌中的紫杉醇耐药性。
Breast Cancer Res. 2015 Jan 13;17(1):5. doi: 10.1186/s13058-014-0512-9.
7
miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.BRCA1 缺陷型三阴性乳腺癌肿瘤中的 miR-146a 和 miR-638，作为改善总体生存的潜在生物标志物。
Cancer Biomark. 2016;16(1):99-107. doi: 10.3233/CBM-150545.
8
Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.雄激素受体拮抗剂联合 PARP1 抑制剂对表达雄激素受体且存在雄激素受体甲基化介导的 BRCA1 功能障碍的散发性三阴性乳腺癌的影响。
Biomed Pharmacother. 2019 Mar;111:169-177. doi: 10.1016/j.biopha.2018.11.136. Epub 2018 Dec 21.
9
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.在日本三阴性乳腺癌中，表皮生长因子受体（EGFR）拷贝数常常增加，而BRCA1 mRNA表达则降低。
BMC Cancer. 2008 Oct 25;8:309. doi: 10.1186/1471-2407-8-309.
10
Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.突尼斯三阴性乳腺癌中 BRCA1 5382insC 突变的贡献。
J Transl Med. 2019 Apr 11;17(1):123. doi: 10.1186/s12967-019-1873-8.

引用本文的文献

1
Treatment strategies targeting the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin pathway against triple-negative breast cancer.针对磷酸肌醇3激酶/蛋白激酶B/雷帕霉素作用机制靶点通路治疗三阴性乳腺癌的策略
World J Clin Oncol. 2025 May 24;16(5):104623. doi: 10.5306/wjco.v16.i5.104623.
2
Bibliometric Analysis of The Global Research Trends on The Application of Tamoxifen in The Treatment of Breast Cancer Over The Past 50 Years.过去50年他莫昔芬在乳腺癌治疗中应用的全球研究趋势的文献计量分析
Malays J Med Sci. 2025 Feb;32(1):35-55. doi: 10.21315/mjms-06-2024-452. Epub 2025 Feb 28.
3

本文引用的文献

1
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.组蛋白去乙酰化酶抑制剂治疗可诱导“BRCA样状态”，并与聚（ADP-核糖）聚合酶（PARP）抑制剂和顺铂协同致死，对抗人三阴性乳腺癌细胞。
Oncotarget. 2014 Jul 30;5(14):5637-50. doi: 10.18632/oncotarget.2154.
2
Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.三阴性乳腺癌的磷酸化激酶谱与雄激素受体信号传导
BMC Cancer. 2014 Apr 30;14:302. doi: 10.1186/1471-2407-14-302.
3
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer.
The treatment of breast cancer in the era of precision medicine.
精准医学时代的乳腺癌治疗
Cancer Biol Med. 2025 Apr 23;22(4):322-47. doi: 10.20892/j.issn.2095-3941.2024.0510.
4
Unveiling role of oncogenic signalling pathways in complicating breast cancer.揭示致癌信号通路在乳腺癌复杂化中的作用。
Biomedicine (Taipei). 2025 Mar 1;15(1):13-21. doi: 10.37796/2211-8039.1640. eCollection 2025.
5
Optimizing Triple-Negative Breast Cancer Therapy via Ultrasound-Enhanced Piezocatalysis for Targeted Chemodrug Release.通过超声增强压电催化实现靶向化疗药物释放以优化三阴性乳腺癌治疗
Int J Nanomedicine. 2025 Mar 6;20:2779-2796. doi: 10.2147/IJN.S505526. eCollection 2025.
6
Identification of transcription factors associated with the disease-free survival of triple-negative breast cancer through weighted gene co-expression network analysis.通过加权基因共表达网络分析鉴定与三阴性乳腺癌无病生存期相关的转录因子。
Cytojournal. 2024 Dec 23;21:71. doi: 10.25259/Cytojournal_127_2024. eCollection 2024.
7
Ethanolic Extract of Leaf Has an Anticancer Activity on Triple-Negative Breast Cancer Cells: An In Vitro Study.叶乙醇提取物对三阴性乳腺癌细胞具有抗癌活性：一项体外研究。
Pharmaceutics. 2024 Dec 24;17(1):2. doi: 10.3390/pharmaceutics17010002.
8
Enhancement of antitumor effects of berberine chloride with a copper(II) complex against human triple negative breast cancer: studies.氯化小檗碱与铜（II）配合物联合增强对人三阴性乳腺癌的抗肿瘤作用：研究
Results Chem. 2024 Dec;12. doi: 10.1016/j.rechem.2024.101882. Epub 2024 Oct 30.
9
Effect of Androgen receptors in Triple-Negative Breast Cancer Given Neoadjuvant Therapy: A Systematic Review and Meta-Analysis.雄激素受体在接受新辅助治疗的三阴性乳腺癌中的作用：一项系统评价和荟萃分析
Asian Pac J Cancer Prev. 2024 Dec 1;25(12):4115-4122. doi: 10.31557/APJCP.2024.25.12.4115.
10
Triple-Negative Breast Cancer: Molecular Particularities Still a Challenge.三阴性乳腺癌：分子特性仍是一项挑战。
Diagnostics (Basel). 2024 Aug 27;14(17):1875. doi: 10.3390/diagnostics14171875.
厄洛替尼联合卡铂治疗三阴性转移性乳腺癌的Ⅱ期临床试验。
Breast Cancer Res. 2014 Mar 31;16(2):R32. doi: 10.1186/bcr3634.
4
Predictive factors and patterns of recurrence in patients with triple negative breast cancer.三阴性乳腺癌患者复发的预测因素及模式
Ann Surg Oncol. 2014 Jul;21(7):2165-71. doi: 10.1245/s10434-014-3546-4. Epub 2014 Feb 21.
5
Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.雄激素受体状态是非基底型三阴性乳腺癌的一个预后标志物，并决定了新的治疗选择。
PLoS One. 2014 Feb 5;9(2):e88525. doi: 10.1371/journal.pone.0088525. eCollection 2014.
6
Association between BRCA Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation.乳腺癌基因突变患者的 BRCA 基因突变状态、病理发现与磁共振成像特征的相关性分析。
J Breast Cancer. 2013 Sep;16(3):308-14. doi: 10.4048/jbc.2013.16.3.308. Epub 2013 Sep 30.
7
Folate receptor α associated with triple-negative breast cancer and poor prognosis.叶酸受体α与三阴性乳腺癌及不良预后相关。
Arch Pathol Lab Med. 2014 Jul;138(7):890-5. doi: 10.5858/arpa.2013-0309-OA. Epub 2013 Sep 13.
8
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.贝伐珠单抗辅助治疗三阴性乳腺癌（BEATRICE）：一项随机、3 期试验的主要结果。
Lancet Oncol. 2013 Sep;14(10):933-42. doi: 10.1016/S1470-2045(13)70335-8. Epub 2013 Aug 7.
9
MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer.MUC1 在早期基底样三阴性乳腺癌中高频表达。
Hum Pathol. 2013 Oct;44(10):2159-66. doi: 10.1016/j.humpath.2013.04.010. Epub 2013 Jul 8.
10
Prevalence of BRCA1 and BRCA2 Germline Mutations in Breast Cancer Women of Multiple Ethnic Region in Northwest China.中国西北地区多民族地区乳腺癌女性中 BRCA1 和 BRCA2 种系突变的流行率。
J Breast Cancer. 2013 Mar;16(1):50-4. doi: 10.4048/jbc.2013.16.1.50. Epub 2013 Mar 31.